Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
plevitrexed · 1 trial · 3 indications
| Name | Type | Description |
|---|---|---|
| plevitrexed | DRUG | - |
| topotecan hydrochloride | DRUG | - |
DISEASE CHARACTERISTICS: Histologically or cytologically confirmed ovarian epithelial cancer, primary peritoneal cancer, or fallopian tube cancer Refractory or recurrent disease after combination platinum and paclitaxel as only prior chemotherapy regimen Platinum resistant (i.e., refractory or relap...
Plevitrexed is an investigational small molecule being studied for the treatment of fallopian tube cancer. It was evaluated in a Phase 2 clinical trial for patients with refractory or recurrent epithelial ovarian cancer, fallopian tube cancer, or primary peritoneal cancer. The drug is still in clinical development and is not approved by the FDA.
Plevitrexed is being developed by AstraZeneca PLC, a biopharmaceutical company traded on the stock exchange under the ticker symbol AZN. The company sponsored a Phase 2 clinical trial of the drug for the treatment of fallopian tube cancer and related gynecologic cancers.
Plevitrexed is in Phase 2 clinical development. It has completed one Phase 2 trial, which was an uncontrolled, non-randomized study. The drug is investigational and has not received FDA approval. No active trials are currently listed for plevitrexed.
Plevitrexed has been studied in one completed clinical trial, identified as NCT00014690. This Phase 2 trial evaluated ZD9331, another name for plevitrexed, with or without topotecan in patients with refractory or recurrent epithelial ovarian cancer, fallopian tube cancer, or primary peritoneal cancer. The trial was conducted in the United States.
Yes, plevitrexed is also known as ZD9331. In clinical trial NCT00014690, the drug was referred to as ZD9331. This alternative name is used in the trial title and is important for identifying the drug in research literature and clinical trial registries.